A Phase 1 interventional study of Plamotamab in Rheumatoid Arthritis, sponsored by Xencor, Inc.. Recruiting at 3 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-03.
Sponsored by Xencor, Inc. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies in Arthritis, Rheumatoid with a site in Georgia — 6 open to participants now, 10 under way, none of them phase 3. Arthritis, Rheumatoid · Georgia.
Among the 34 studies in Arthritis, Rheumatoid with a site in Georgia, this one is the 27th largest by planned enrollment, is one of 6 that started in 2025, is one of 8 in phase 1, and was the 31st registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →6 of the 34 studies in Arthritis, Rheumatoid with a site in Georgia are open now. Recruiting first, the newest first:
PTC Therapeutics · Sites in Georgia, United States, Mauritius and 1 more country
Ages 18–70
SciRhom GmbH · Sites in Georgia, Moldova, Romania
Ages 18–60
Merck Sharp & Dohme LLC · Sites in Georgia, Australia, Belgium and 8 more countries
Ages 18–75
Lifordi Immunotherapeutics, Inc. · Sites in Georgia, Australia, Moldova and 2 more countries
Ages 18–75 · Healthy volunteers
Sanofi · Sites in Georgia, Australia, Bosnia and Herzegovina and 2 more countries
Ages 18–75
A study can be open while its sites in Georgia have not opened yet or have stopped. Only those recruiting at a site in Georgia →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 6 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 68 is below the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 135 across the 34 interventional studies. Of the 24 that completed or were terminated, 13 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 34 have an industry lead sponsor. The 10 most frequent:
Xencor, Inc. is the lead sponsor of 30 studies on the registry; 7 are open to participants now.
Of its 15 completed or terminated interventional studies of FDA-regulated products, 2 (13%) have results posted.
Xencor, Inc. has 1 study filed under Arthritis, Rheumatoid — fewer than ten, so there is no comparison to draw.
4 of the studies in Arthritis, Rheumatoid with a site in Georgia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06902519Gilead SciencesStudy of GS-0151 in Participants With Rheumatoid Arthritis | 2027-03 |
| NCT07207954Lifordi Immunotherapeutics, Inc.Study of LFD-200 in Healthy Adults and Adults With Moderate to Severe Rheumatoid Arthritis | 2027-07-16 |
| NCT06754462Immunovant Sciences GmbHA Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid Arthritis | 2027-09 |
| NCT07779616PTC TherapeuticsStudy of PTC844 in Participants With Active Rheumatoid Arthritis | 2027-09-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 34 studies in Arthritis, Rheumatoid with a site in Georgia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the safety and tolerability of plamotamab in patients with rheumatoid arthritis. Participants will be given XmAb13676 subcutaneously (SC) by injection under the skin.
This is a Phase 1b study to determine the safety, tolerability, pharmacokinetic (PK), and pharmacodynamics (PD), and immunogenicity of plamotamab in adult participants with moderately to severely active RA. This is an open label dose optimization trial with approximately 68 participants assigned to different dose escalation cohorts.
Inclusion Criteria: Adult participants with moderately to severely active RA.
Exclusion Criteria:
Note: Additional, more specific inclusion/exclusion criteria are defined in the protocol.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Plamotamab administered SC
Biological: Plamotamab
Biological
Primary
Percentage of participants with treatment emergent adverse events (TEAEs) and serious adverse events (SAEs)
Time frame: Through Week 52
Secondary
Serum concentration of plamotamab
Time frame: Through Week 52
Started Oct 2025 (actual). Primary completion is estimated for Jun 2028, 32 months after the start.
Of 128 industry-sponsored phase 1 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 32. This study's planned 32 months is above that.
Counting every sponsor, half of 148 studies reached it within 16 months; a quarter within 5 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Plamotamab